ESPE Abstracts

On 01/14/2021, the European Commission authorized the marketing of Baqsimi® 3 mg (nasal glucagon), a powder medicine, ready to be used, in the treatment of severe hypoglycemia in adults, adolescents and children over four years of age with diabetes mellitus. Baqsimi® is the first and only nasal glucagon treatment available approved in the European Union (EU), and has been designed as a rescue treatment in cases of severe hypoglycemia, being absorbed passively into the nasal mucosa after its administration.. The safety data obtained from these studies demonstrated that nasal glucagon is well tolerated as an emergency treatment of severe hypoglycaemia in adult and pediatric patients with diabetes 4 years of age and older. The most frequently reported adverse reactions in the adult population associated with its use were increased lacrimation (36%), irritation of the upper respiratory tract (34%), nausea (27%), headache (21%) and vomiting (16 %).

Objective: To evaluate the clinical experience in incorporating BAQSIMI into routine clinical practice.

Methods: DM1 patients over 4 years old, enrolled in school, from the start of follow-up in specialty consultations at our center. Previous use of GLUCAGEN hipoKIT. Assessment of age, sex, weight, height, BMI (Carrascosa 20210), age of debut, HbA1c. Descriptive study IBM SPSS Stastistics 19.0.

Results: 68 children older than 4 years (35♂), mean age 9.5 to [4-17]. HbA1c (DCA): 7.7% [6.8-9.2], time to debut 3.8a [0.8-10.1], mean weight -0.32 SDS [-1.2, + 0.8], mean BMI - 0.28 SDS [-1.4, + 0.9]. 93% use of MDI, 5 pumps. 100% correct use of inhaled glucagon. There was no impediment due to medical inspection except in 1 case (belonging to another health area). Previous severe hypoglycemia with previous loss of consciousness in <5% of cases (0.03 patient / year cases). Number of recipes made 70. (67 unique + 3 multiples). 3 episodes of severe hypoglycemia (loss of consciousness, crisis) (2 in the same patient) associated with exercise + incomplete intake and / or incorrect bolus calculation. The 3 cases in MDI. Use of Baqsimi in all 3 cases. Recovery from the episode WITHOUT sequelae and almost immediately. Symptoms manifested: tearing (33%), irritation of the upper respiratory tract (33%), nausea (33%), headache (66%) and vomiting (33%). Paternal evaluation: excellent (3/3).

Conclusion: We assume that this study may have some shortcomings due to the size of the sample, but our study demonstrates the efficacy of inhaled glucagon in emergency situations in real life, its good tolerance and its excellent reception by families.